321 related articles for article (PubMed ID: 8639809)
1. Murine gamma/delta-expressing T cells affect alloengraftment via the recognition of nonclassical major histocompatibility complex class Ib antigens.
Blazar BR; Taylor PA; Bluestone JA; Vallera DA
Blood; 1996 May; 87(10):4463-72. PubMed ID: 8639809
[TBL] [Abstract][Full Text] [Related]
2. Lethal murine graft-versus-host disease induced by donor gamma/delta expressing T cells with specificity for host nonclassical major histocompatibility complex class Ib antigens.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Barrett TA; Bluestone JA; Vallera DA
Blood; 1996 Jan; 87(2):827-37. PubMed ID: 8555509
[TBL] [Abstract][Full Text] [Related]
3. Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice.
Drobyski WR; Majewski D
Blood; 1997 Feb; 89(3):1100-9. PubMed ID: 9028343
[TBL] [Abstract][Full Text] [Related]
4. The role of host T cell subsets in bone marrow rejection directed to isolated major histocompatibility complex class I versus class II differences of bm1 and bm12 mutant mice.
Vallera DA; Taylor PA; Sprent J; Blazar BR
Transplantation; 1994 Jan; 57(2):249-56. PubMed ID: 7906058
[TBL] [Abstract][Full Text] [Related]
5. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
Drobyski WR; Majewski D
Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
[TBL] [Abstract][Full Text] [Related]
6. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow.
Blazar BR; Taylor PA; Sehgal SN; Vallera DA
Blood; 1994 Jan; 83(2):600-9. PubMed ID: 8286755
[TBL] [Abstract][Full Text] [Related]
8. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
[TBL] [Abstract][Full Text] [Related]
9. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism.
Martin PJ
Blood; 1996 Aug; 88(3):962-9. PubMed ID: 8704255
[TBL] [Abstract][Full Text] [Related]
10. Effect of recombinant human macrophage colony-stimulating factor in irradiated murine recipients of T-cell-depleted allogeneic or non-depleted syngeneic bone marrow transplants.
Blazar BR; Aukerman SL; Vallera DA
Blood; 1992 Mar; 79(6):1636-42. PubMed ID: 1547353
[TBL] [Abstract][Full Text] [Related]
11. Adoptively transferred gamma delta T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice.
Drobyski WR; Vodanovic-Jankovic S; Klein J
J Immunol; 2000 Aug; 165(3):1634-40. PubMed ID: 10903774
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
[TBL] [Abstract][Full Text] [Related]
13. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
14. Tolerance induction in a fully allogeneic combination using anti-T cell receptor-alpha beta monoclonal antibody, low dose irradiation, and donor bone marrow transfusion.
Nomoto K; Yung-Yun K; Omoto K; Umesue M; Murakami Y; Matsuzaki G; Nomoto K
Transplantation; 1995 Feb; 59(3):395-401. PubMed ID: 7871570
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
16. Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene.
Drobyski WR; Morse HC; Burns WH; Casper JT; Sandford G
Blood; 2001 Apr; 97(8):2506-13. PubMed ID: 11290616
[TBL] [Abstract][Full Text] [Related]
17. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.
Koch U; Korngold R
Blood; 1997 Apr; 89(8):2880-90. PubMed ID: 9108408
[TBL] [Abstract][Full Text] [Related]
18. Promotion of murine marrow alloengraftment and hematopoietic recovery across the major histocompatibility barrier by administration of recombinant human interleukin-1 alpha.
Blazar BR; Widmer MB; Taylor PA; Vallera DA
Blood; 1992 Sep; 80(6):1614-22. PubMed ID: 1369829
[TBL] [Abstract][Full Text] [Related]
19. Influence of the additional injection of host-type bone marrow on the immune tolerance of minor antigen-mismatched chimeras: possible involvement of double-negative (natural killer) T cells.
Sefrioui H; Billiau AD; Overbergh L; Rutgeerts O; Waer M
Transplantation; 1999 Nov; 68(10):1560-7. PubMed ID: 10589955
[TBL] [Abstract][Full Text] [Related]
20. Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via In utero or postnatal transfer.
Blazar BR; Taylor PA; McElmurry R; Tian L; Panoskaltsis-Mortari A; Lam S; Lees C; Waldschmidt T; Vallera DA
Blood; 1998 Nov; 92(10):3949-59. PubMed ID: 9808589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
